MannKind Corporation (NASDAQ:MNKD) issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.10, RTT News reports. The company had revenue of $2.16 million during the quarter, compared to analyst estimates of $2.75 million. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. During the same quarter last year, the firm earned $0.08 EPS.
Shares of MannKind Corporation (NASDAQ:MNKD) traded up 4.29% during midday trading on Friday, reaching $1.46. The company’s stock had a trading volume of 2,357,104 shares. MannKind Corporation has a 1-year low of $0.41 and a 1-year high of $2.38. The stock has a 50 day moving average of $1.27 and a 200-day moving average of $1.26. The company has a market capitalization of $152.84 million, a P/E ratio of 1.10 and a beta of 3.30.
COPYRIGHT VIOLATION NOTICE: “MannKind Corporation (NASDAQ:MNKD) Issues Quarterly Earnings Results” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/08/19/mannkind-corporation-nasdaqmnkd-releases-quarterly-earnings-results-misses-estimates-by-0-10-eps-updated.html.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
What are top analysts saying about MannKind Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MannKind Corporation and related companies.